38 results
8-K
EX-99.1
NRBO
NeuroBo Pharmaceuticals Inc
22 Sep 23
Regulation FD Disclosure
8:03am
on Chronic Liver and Related Metabolic Diseases Product Preclinical Phase 1 Phase 2 Upcoming Catalysts DA-1241 (GPR119 Agonist) 2H 2023: initiation of Part 2 … effect ➢ DA-1241 showed no noteworthy safety concerns in safety pharmacology and toxicology studies up to 26 & 39-week chronic dosing in rats
424B4
NRBO
NeuroBo Pharmaceuticals Inc
7 Nov 22
Prospectus supplement with pricing info
9:07am
success of semaglutide (WEGOVY®), a drug recently approved for the treatment of chronic weight management in adults with obesity. With the success … in overnight fasted mice.
In diabetic mice with hypertriglyceridemia, chronic treatment with DA-1241 lowered fasting and non-fasting blood glucose levels
FWP
oyxgeargid oxvybl
24 Oct 22
Free writing prospectus
4:38pm
8-K
EX-99.1
xdp4w2wnu5 b4q7mz
15 Nov 21
NeuroBo Pharmaceuticals Reports Third Quarter 2021 Financial Results
8:18am
8-K
EX-99.1
h1t5xx
4 Nov 21
NeuroBo Pharmaceuticals Appoints Gil Price, M.D. as President
8:10am
8-K
EX-99.1
3q042g6cqkvtaiyr0sl
4 Oct 21
Neurobo Pharmaceuticals Announces $14 Million Registered Direct Offering
4:46pm
8-K
EX-99.1
t9ta5d
16 Aug 21
NeuroBo Pharmaceuticals Reports Second Quarter 2021 Financial Results
8:13am
8-K
EX-99.1
l092xz37 pymr
12 Jul 21
NeuroBo Pharmaceuticals’ Shareholders Elect Hyung Heon Kim and Andrew I. Koven to NeuroBo’s Board of Directors
8:41am
8-K
EX-99.1
nbkool
17 May 21
NeuroBo Pharmaceuticals Reports First Quarter 2021 Financial Results
5:03pm
8-K
EX-99.1
x3jrvj3l
15 Apr 21
NeuroBo Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Strategic Update
4:58pm
8-K
EX-99.1
dmz8g5q32dv0bf
24 Mar 21
NeuroBo Pharmaceuticals Receives Approval for Amendment of Contingent Value Rights for Gemcabene
8:15am
8-K
EX-99.1
gzntrnwf
5 Mar 21
Company Presentation Confidential March 2021
8:41am
8-K
EX-99.2
2jvu3qxp
21 Jan 21
NeuroBo Pharmaceuticals Announces $10.0 Million Private Placement
5:03pm